Reply to Siddiqui et al., Godbout et al., and to Chang and Mao.

Chupp G., Nagase H., Skowasch D., Devouassoux G., Côté A., Jackson DJ., Jackson DJ., Wechsler ME., Howarth P., Pavord ID., “Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)” .

DOI

10.1093/ajrccm/aamag300

Type

Journal article

Publication Date

2026-06-24T00:00:00+00:00

Permalink More information Close